In this interview from the ASRS 2013 Annual Meeting, Dr. Carl C. Awh discusses his study showing that genetic polymorphisms predict how patients with age-related macular degeneration (AMD) respond to antioxidants and zinc. His pharmacogenetic analysis of AREDS patients showed that about half would have done better taking a vitamin formulation other than AREDS. Patients with moderate AMD and no CFH risk alleles and with 1 or 2 ARMS2 risk alleles derived maximum benefit from zinc-only supplementation, while those with one or two CFH risk alleles and no ARMS2 risk alleles did better with antioxidant-only supplementation.